Sulfotransferase sequence variants

Abstract

Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described. Methods for determining a risk estimate for hormone dependent disease and methods for determining sulfonator status also are described.

1 - 17 . (Canceled).  
     
     
         18 . A method for determining sulfonator status in a subject, said method comprising detecting the presence or absence of a sulfotransferase allozyme in said subject, and determining said sulfonator status based, at least in part, on presence or absence of said sulfotransferase allozyme.  
     
     
         19 - 31 . (Canceled).  
     
     
         32 . A method for determining the sulfonator status of an individual, said method comprising determining whether said subject comprises a variant SULT1A1, SULT1A2, or SULT1A3 nucleic acid.  
     
     
         33 . The method of  claim 32 , wherein said variant SULT1A1 nucleic acid comprises an adenine at nucleotide 638.  
     
     
         34 . The method of  claim 32 , wherein said variant SULT1A1, SULT1A2, or SULT1A3 nucleic acid comprises the SULT1A1*2 allele.  
     
     
         35 . A method for predicting the therapeutic efficacy of a compound in a subject, wherein said compound is sulfonated, said method comprising: 
 a) determining the sulfonator status of said subject; and    b) correlating said sulfonator status with the ability of said subject to metabolize said compound, wherein said compound is predicted to be therapeutically effective if said sulfonator status is enhanced in said subject, and wherein said compound is predicted not to be therapeutically effective if said sulfonator status is reduced in said subject.    
     
     
         36 . The method of  claim 35 , wherein said determining of said sulfonator status comprises determining whether said subject comprises a variant SULT1A1, SULT1A2, or SULT1A3 nucleic acid.  
     
     
         37 . The method of  claim 36 , wherein said variant SULT1A1, SULT1A2, or SULT1A3 nucleic acid comprises a non-synonymous single nucleotide polymorphism.  
     
     
         38 . The method of  claim 35 , wherein said determining of said sulfonator status comprises measuring sulfotransferase activity in a sample from said subject.  
     
     
         39 . The method of  claim 38 , wherein said sample is a blood sample.  
     
     
         40 . The method of  claim 38 , wherein said sulfotransferase activity is SULT1A1, SULT1A2, or SULT1A3 activity.  
     
     
         41 . A method for predicting the therapeutic efficacy of a compound in a subject, wherein metabolism of said compound comprises sulfonation, said method comprising: 
 a) estimating the level of sulfotransferase activity in said subject; and    b) correlating said level of sulfotransferase activity with the ability of said subject to metabolize said compound, wherein said compound is predicted to be therapeutically effective if said level of sulfotransferase activity is increased in said subject, and wherein said compound is predicted not to be therapeutically effective if said level of sulfotransferase activity is reduced in said subject.    
     
     
         42 . The method of  claim 41 , wherein said sulfotransferase is SULT1A1, SULT1A2, or SULT1A3.  
     
     
         43 . The method of  claim 41 , wherein said level of sulfotransferase activity in said subject is estimated by determining whether said subject comprises a variant SULT1A1, SULT1A2, or SULT1A3 nucleic acid.  
     
     
         44 . The method of  claim 43 , wherein said variant SULT1A1, SULT1A2, or SULT1A3 nucleic acid comprises a non-synonymous single nucleotide polymorphism.  
     
     
         45 . A method for estimating a dose of a compound for administration to a subject, wherein metabolism of said compound comprises sulfonation, said method comprising determining the sulfonator status of said subject, wherein said dose is estimated to be higher if said sulfonator status is increased in said subject, and wherein said dose is estimated to be lower if said sulfonator status is decreased in said subject.  
     
     
         46 . The method of  claim 45 , wherein determination of said sulfonator status comprises determining whether said subject comprises a variant SULT1A1, SULT1A2, or SULT1A3 nucleic acid.  
     
     
         47 . The method of  claim 46 , wherein said variant SULT1A1, SULT1A2, or SULT1A3 nucleic acid comprises a non-synonymous single nucleotide polymorphism.